Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
On March 5, 2025, Gilead Sciences (GILD) displayed steady intraday performance amid key regulatory, financial, and strategic developments.
Gilead Sciences (GILD) navigates growth in HIV, liver disease, and oncology, driven by key products and strategic collaborations. Lenacapavir and Seladelpar offer market expansion.
Gilead Sciences (GILD) navigates a dynamic landscape, leveraging its HIV dominance while expanding in oncology and Europe. Approvals signal growth, but a high P/E requires caution.
Gilead Sciences sees a resurgence with FDA priority review for Lenacapavir, European approval for Seladelpar, and strong Q4 2024 results, signaling strategic growth.
Gilead Sciences navigates regulatory milestones with Lenacapavir and Seladelpar, faces Medicare reforms, and prepares for investor conferences. Innovation and strategic expansion are key.
Gilead Sciences advances with FDA review for Lenacapavir and EU approval for Seladelpar, boosting growth prospects.
Gilead Sciences navigates regulatory milestones, pipeline adjustments, and strategic priorities, impacting its market position and future growth. A comprehensive intraday update.
Gilead Sciences' latest update highlights FDA priority review for Lenacapavir and strong Q4 earnings, underscoring its leadership in HIV prevention.
Gilead Sciences update highlights lenacapavir FDA NDA acceptance, strong Q4 earnings, and pipeline growth.